Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT
Phathom Pharmaceuticals — Technical Presentation (October 2024)
10 slides from Phathom Pharmaceuticals's technical presentation, October 2024
Slide 1: Heartburn Frequency and Symptom Improvement Rates When Switching From Daily to On-Demand Vonoprazan
HEARTBURN FREQUENCY AND SYMPTOM IMPROVEMENT RATES OF TREATED EPISODES WHEN SWITCHING FROM DAILY TO ON-DEMAND VONOPRAZAN TREATMENT FOR NON-EROSIVE REFLUX DISEASE Ronnie Fass1, Joan W. Chen2, Joel J. Heidelbaugh2, Anish Patel3, Reena V. Chokshi4, Tom Harris5, Hillary Graham5, Eckhard Leifke5, David Ar
Slide 2: Background
Background Vonoprazan,* a P-CAB, is a good On-demand treatment for Current options for on-demand candidate for on-demand non-erosive GERD is suitable if: dosing are limited therapy3-5 • Patients do not have high • Antacids and H2 receptor • Rapid onset and potent acid frequency of heartburn antagoni
Slide 3: Background: NERD-201 phase 2 study
Background 80 *** The NERD-201 phase 2 study1 70 *** 70 reported that vonoprazan 60 *** 56 60.6 on-demand was significantly better Episodes, % 50 than placebo in providing rapid and 40 sustained relief from evaluable 30 27.3 heartburn episodes in patients with 20 NERD who had responded to 10 4 weeks
Slide 4: Aim
Aim This is a post hoc analysis that evaluates: • Frequency of heartburn episodes when switching to on-demand treatment after achieving symptom control with daily treatment • Rate of symptom improvement of treated episodes October 25-30, Philadelphia, PA
Slide 5: Methods
Methods • Patients eligible to enter the on-demand period: • Completed run-in period of daily vonoprazan 20 mg for 4 weeks • Were 80% compliant with run-in period study drug and electronic diary entries • Reported no heartburn during the last seven days of run-in period Vonoprazan 10 mg On-Demand Vo
Slide 6: Results: % of Heartburn-Free Days by Study Period
Results: % of Heartburn-Free Days by Study Period Screening Run-In On-Demand • Patients randomized to on-demand treatment phase were highly symptomatic during screening, with only 16.1% of days heartburn-free. • With daily vonoprazan treatment during the run-in period, symptom control was achieved,
Slide 7: Results: % of Heartburn-Free Days by Study Week
Results: % of Heartburn-Free Days by Study Week Heartburn-free days were consistent over the entire 6-week on-demand treatment period. On-demand ITT (intention to treat) population. All patients received vonoprazan 20 mg during the run-in phase October 25-30, Philadelphia, PA
Slide 8: Results: % of Heartburn Episodes Improved After Treatment
Results: % of Heartburn Episodes Improved After Treatment Differences between each vonoprazan dose compared to placebo were evident within the first hour. Over 90% of episodes treated with vonoprazan improved by 2 hours. **p< 0.05; ***p< 0.0001 for difference from placebo October 25-30, Philadelphia
Slide 9: Results: Consistency of Improvement Across Initial Episode Severity
Results: Consistency of Improvement Across All Levels of Initial Episode Severity Episodes starting as Mild Episodes starting as Moderate *** Episodes starting as Severe or Very Severe *p< 0.1 **p< 0.05; ***p< 0.0001 for difference from placebo October 25-30, Philadelphia, PA
Slide 10: Conclusions
Conclusions • Upon achieving symptom control with daily vonoprazan treatment, a high rate of heartburn-free days was sustained when switching to on-demand therapy over the 6-week placebo-controlled period • Initial 4-week run-in period produced a durable reduction in heartburn symptoms that allows c
Phathom Pharmaceuticals — Technical Presentation (October 2024) on 6ix